<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Boyer, N.</title>
    <link>http://repub.eur.nl/res/aut/13445/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/8295/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: The key end point for treatment efficacy in chronic hepatitis
      C is absence of detectable virus at six months after treatment. However,
      the incidence of clinical events during long term follow up of patients
      with sustained virological response is still poorly documented and may
      differ between the Eastern and Western world. AIMS: To assess clinical end
      points during long term follow up of European patients with a sustained
      virological response to interferon monotherapy. METHODS: Meta-analysis of
      individual patient data from eight European protocolled follow up studies
      of interferon treatment for chronic hepatitis C. RESULTS: A total of 286
      sustained virological responders and 50 biochemical responders (detectable
      virus but normal alanine aminotransferase levels) were followed up for 59
      months. Fifteen sustained virological responders (5.2%) had cirrhosis
      before treatment and 112 (39%) had genotype 1. The late virological
      relapse rate after five years of follow up was 4.7% (95% confidence
      interval (CI) 2.0-7.4) among sustained virological responders; all late
      relapses occurred within four years after treatment. Among sustained
      virological responders, the rate of decompensation after five years of
      follow up was 1.0% (95% CI 0.0-2.3) and none developed hepatocellular
      carcinoma (HCC). Survival was comparable with the general population,
      matched for age and sex, the standard mortality ratio being 1.4 (95% CI
      0.3-2.5). Clinical outcome of patients with cirrhosis was similar to other
      sustained virological responders. For biochemical responders, the rates of
      development of decompensation and HCC during long term follow up were 9.1%
      (95% CI 0.5-17.7) and 7.1% (95% CI 0-15.0), respectively. CONCLUSIONS:
      Five year survival of European sustained virological responders was
      similar to the overall population, matched for age and sex. No HCCs were
      detected during long term follow up.</description>
    </item>
  </channel>
</rss>